Powered by

National Institutes of Health Awards Boragen $300,500 Grant for Antimalarial Drug Discovery

Jul 21, 2020 - Business Wire

Boragen, Inc. , a world-leading boron-based discovery platform company, has been awarded a $300,500 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

The SBIR grant will further accelerate the collaboration with the University of California, San Francisco (UCSF), that focuses on effective control for the protozoan parasite Plasmodium, the causative agent for malaria.

The project takes a 2-pronged approach, starting with leveraging Boragen's unique diverse boron-based small molecule library to identify new targets and modes of action for inhibiting Plasmodium. Secondly, "acknowledging that there is a strong interplay between inflammation and most human diseases, including infectious diseases like malaria, we are also looking into a strategy that could both inhibit the parasite and provide the relevant anti-inflammatory effect," said Dr. Tony Liu, Boragen's Chief Scientific Officer and Co-Found...